Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721876 · ClinicalTrials.gov registry record · Phase 3
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 666
- Enrollment target
NCT01721876 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 666 participants.
The verdict
NCT01721876, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 666 participants
- Enrollment target
Study Summary
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients \>= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy
Interventions
- DRUG Placebo
- DRUG Cytarabine
- DRUG Volasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 666 participants |
| Start Date | 2013-01-29 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721876
The ClinicalTrials.gov registry entry for NCT01721876 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 666 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01721876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721876 about?
NCT01721876 is a clinical study titled "Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)". To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients \>= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy
What is the current status of trial NCT01721876?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 666 participants. The study started on 2013-01-29. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT01721876?
The interventions under investigation include: Placebo (DRUG), Cytarabine (DRUG), Volasertib (DRUG).
Who is sponsoring clinical trial NCT01721876?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.